# No Treatment Versus Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants

Study · id `cardio:ct-nct02128191` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02128191](<https://clinicaltrials.gov/study/NCT02128191>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02128191

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.

## Technical summary

Registry record NCT02128191. Randomized; quadruple masking; primary purpose treatment. Start 2014-07 (actual); primary completion 2019-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 142 participants (enrolled count; ClinicalTrials.gov record NCT02128191, source copy `cardio:ctgov-nct02128191-2020-01-13`, retrieved 2026-10-26)
- Started: 2014-07 (actual) (ClinicalTrials.gov record NCT02128191, source copy `cardio:ctgov-nct02128191-2020-01-13`, retrieved 2026-10-26)
- Primary completion: 2019-08 (actual) (ClinicalTrials.gov record NCT02128191, source copy `cardio:ctgov-nct02128191-2020-01-13`, retrieved 2026-10-26)
- Completion: 2019-08 (actual) (ClinicalTrials.gov record NCT02128191, source copy `cardio:ctgov-nct02128191-2020-01-13`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02128191, source copy `cardio:ctgov-nct02128191-2020-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02128191-2020-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: No Treatment Versus Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants
- Condition: Bronchopulmonary Dysplasia (BPD)
- Intervention (Drug): Oral ibuprofen
- Intervention (Drug): Normal saline
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: 1326bfb7f5c88dee4c2167cbecb2d8b984cb5b5e8814d929089d0ea5e7d767cc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
